Research and Markets: Ebola and Marburg Infections - Pipeline Insights 2014

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/qq289p/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections-Pipeline Insights, 2014" subscription to their offering.

This Ebola and Marburg Infections-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Ebola and Marburg Infections.

This report provides information on the therapeutic development based on the Ebola and Marburg Infections dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.

The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ebola and Marburg Infections
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Ebola and Marburg Infections pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Ebola and Marburg Infections and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Ebola and Marburg Infections Overview
  2. Ebola and Marburg Infections Pipeline Therapeutics
  3. Ebola and Marburg Infections Therapeutics under Development by Companies
  4. Ebola and Marburg Infections Late Stage Products (Filed and Phase III)
  5. Comparative Analysis
  6. Ebola and Marburg Infections Mid Clinical Stage Products (Phase II)
  7. Comparative Analysis
  8. Ebola and Marburg Infections Early Clinical Stage Products (Phase I and IND Filed)
  9. Comparative Analysis
  10. Ebola and Marburg Infections Discovery and Pre-Clinical Stage Products
  11. Comparative Analysis
  12. Drug Candidate Profiles
  13. Ebola and Marburg Infections - Therapeutics Assessment
  14. Assessment by Monotherapy Products
  15. Assessment by Combination Products
  16. Assessment by Route of Administration
  17. Assessment by Molecule Type
  18. Ebola and Marburg Infections - Discontinued Products
  19. Ebola and Marburg Infections - Dormant Products
  20. Companies Involved in Therapeutics Development for Ebola and Marburg Infections

For more information visit http://www.researchandmarkets.com/research/qq289p/ebola_and_marburg

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals